Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
Scientific Community
Become a Member | Sign in
Home>News>This Article

Key Mesenchymal Precursor Cell Patents Granted in United States and China

Published: Friday, February 08, 2013
Last Updated: Thursday, February 07, 2013
Bookmark and Share
New granted claims confer exclusive, long-term commercial rights in the world's largest established and emerging healthcare markets.

Regenerative medicine company Mesoblast Limited has announced that it has been granted three key new patents by the United States Patent and Trade Mark Office (USPTO) and the State Intellectual Property Office of the People’s Republic of China.

These patents deliver major commercial advantages and offer long term protection in these territories for the company’s products based on its proprietary Mesenchymal Precursor Cell (MPC) adult stem cell technology platform.

In the United States, USPTO patent 8,367,405 confers Mesoblast with exclusive rights through to March 2029 to compositions-of-matter covering its current products.

This patent extends by more than seven years Mesoblast's exclusive commercial rights in the United States, the world’s largest healthcare market, to MPC compositions-of-matter beyond those rights already conferred by USPTO patents 7,122,178 and 8,158,118 whose expiry had previously been extended to November 2021.

In China, patents CN200580040212.1 and CN200580039970.1 provide Mesoblast with exclusive MPC product commercial rights and protection through to 2025.

These patents provide Mesoblast with long-term composition-of-matter protection for the company's MPC products derived from an unlimited range of tissue sources, such as bone marrow, adipose tissue, placenta, umbilical cord, and dental pulp.

These Chinese patents underpin Mesoblast's corporate strategy to target the world’s largest emerging market for regenerative medicines, and to protect its manufacturing processes and know-how.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pharmaceutical Executive Joins Mesoblast as Chief Financial Officer
Appointment of Mr Paul Hodgkinson as Company’s Chief Financial Officer.
Tuesday, August 26, 2014
FDA Agreement on Mesoblast’s Use of Singapore Manufacturing Facility for MPCs Clinical Trial Production
New facility will support product delineation strategies, increase geographical reach, and reduce risk of single site reliance.
Tuesday, May 21, 2013
Mesoblast Receives FDA Clearance for Phase 2 Trial of MPCs in Active RA Patients
In addition, a second Phase 2 trial of MPCs as a first-line biologic treatment for active RA is planned to commence in Europe in 1H 2013.
Thursday, May 16, 2013
Mesoblast Completes A$170m Private Placement
Company now has cash reserves of approximately A$332 million.
Tuesday, March 19, 2013
Mesoblast Reports Half-Year 2013 Financial Results
Provides strategic update on key areas of product development.
Tuesday, February 12, 2013
New Teva Representative Joins Mesoblast Board Of Directors
Appointment of Dr Ben-Zion Weiner as a non-executive Director of Mesoblast.
Monday, October 22, 2012
Mesoblast Provides Corporate Strategy for Product Development to Treat Neurologic Conditions
Exclusive commercial rights to develop neuroregenerative dental pulp stem cells.
Tuesday, June 12, 2012
Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Proprietary Stem Cell Therapy in Type 2 Diabetes
Trial will be randomized, placebo-controlled to evaluate safety and effectiveness over 3 months of a single intravenous injection of one of three progressively increasing MPC doses in 60 Type 2 diabetes patients with elevated blood glucose levels.
Tuesday, May 08, 2012
Intervertebral Disc Repair Phase 2 Trial Update
Rapid patient accrual, enrolment reaches half way mark positive preclinical study results published in premier neurosurgical journal.
Wednesday, April 18, 2012
Mesoblast Half-Year Results
Strong financial position underpins company’s ability to deliver in increased value from broadened range of stem cell therapeutics.
Tuesday, February 28, 2012
Mesoblast Presented Positive Phase 2 Results at AHA
Revascor™ anticipated to progress to Phase 3 trial in first half of 2012.
Friday, November 18, 2011
Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases
Mesoblast receives regulatory clearance to begin Phase 2 trial for wet Age-related Macular Degeneration.
Thursday, October 27, 2011
Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or ‘Off-The-Shelf’ Stem Cell Treatment for Heart Attacks
Company receives clearance to begin Phase 2 clinical trial for Revascor™ in conjunction with angioplasty and stent procedures.
Tuesday, September 06, 2011
Single Dose of Proprietary Adult Stem Cells Regenerates Damaged Pancreas
Stem cell treatment induced two-fold increase in total numbers of pancreatic islets, and increase in insulin-producing beta cells.
Monday, December 21, 2009
Mesoblast's Stem Cells Protect Knee Cartilage in Osteoarthritis
Mesoblast's allogeneic, or donor unrelated, adult stem cells protected knee joint cartilage against destruction in osteoarthritis preclinical trials.
Wednesday, August 29, 2007
Scientific News
Fat Cells Originating from Bone Marrow Found in Humans
Cells could contribute to diabetes, heart disease.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
CRI Identifies Emergency Blood-formation Response
Researchers report that when tissue damage occurs, an emergency blood-formation system activates.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
The Life Story of Stem Cells
A model analyses the development of stem cell numbers in the human body.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Advancing Genome Editing of Blood Stem Cells
Genome editing techniques for blood stem cells just got better, thanks to a team of researchers at USC and Sangamo BioSciences.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos